Cannabis Law Report
DECEMBER 7, 2021
On November 16, 2021, the Drug Enforcement Agency (DEA) issued an advance notice of proposed rulemaking , exploring whether or not to create new federal regulations governing the practice of telepharmacy. The DEA’s notice provides the industry with an opportunity to provide insight and feedback that may help shape the new regulations.
CannaMD
NOVEMBER 15, 2020
His findings are sure to alarm medical cannabis professionals and patients alike. research funders, the National Institute on Drug Abuse (NIDA) , spent over $1 billion between 2000 and 2008, with a heavily slanted focus on cannabis abuse and misuse, as well as the negative effects of cannabis. Funding of Marijuana Research.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
APRIL 8, 2022
Later that year, Doblin sued the DEA for the first time. submitted his first DEA application to manufacture marijuana for use in medical research. On May 3, 2021, our study of MDMA-assisted therapy for PTSD achieved successful results for patients with severe, chronic PTSD. Lyle Craker, Ph.D., Source: [link].
Cannabis Law Report
JULY 12, 2019
Side effects were very prevalent in 79% of all patients taking a refined CBD product, some of which were severe like thrombocytopenia and transaminase elevations in the liver. Review: During an open-label trial of pure CBD with Lennox-Gastaut and Dravet patients, 79% of all patients reported side effects.
The Herb Collective
JUNE 25, 2018
According to Trend Statistics, there are over 2,604,079 medical marijuana patients in 2016, with 19.8 patients per thousand residents in Colorado, 19.4 patients per thousand residents in Phoenix AZ, Las Vegas NV, and California, and 19.2 patients per thousand residents in Washington and Oregon. Source: Cannabisser) 10.
The Cannigma
SEPTEMBER 12, 2021
Depending on the state you’re in, THC products may be legally accessible to any adult, and other states restrict access to medical patients only. Marijuana (defined in the US as any cannabis plant where THC>0.3%) is a schedule I drug according to the DEA and FDA. in 2008, 12% in 2012 and 15% in 2018. THC in 1993, 8.8%
Cannabis Law Report
MARCH 25, 2019
The DEA has made previous requests–in 2001 and 2006–to the FDA for an evaluation of marijuana. But DEA regulators determined after both of those reviews that marijuana should remain a Schedule I substance. 15, 2008 , 122 Stat. 2003, 2004, 2007, 2008, Nov. 109–177, title VII , §§ ? 711(f)(1)(B), 732, Mar.
Expert insights. Personalized for you.
52 
Let's personalize your content